• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Abstract 1341: Endocrine deprivation therapy increases the sensitivity of breast cancer cells to T cell-mediated lysis independently of estrogen receptor or androgen receptor status
Estrogen deprivation therapy has been used as the first line adjuvant hormonal therapy for breast cancer for over 20 years. Tamoxifen, the first drug discovered to inhibit estrogen receptor signaling, is used to treat premenopausal women with estrogen receptor positive tumors. Although tamoxifen can be therapeutic in most women with estrogen receptor positive tumors, some women do not respond and others eventually develop resistance. In addition, tamoxifen has minimal effect on the growth of estrogen receptor negative tumors, including triple negative breast cancer, which has the poorest prognosis. Furthermore, prolonged a...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Kwilas, A. R., Ardiani, A., Gameiro, S. R., Hodge, J. W. Tags: Immunology Source Type: research

Risk-Benefit Profiles of Women Using Tamoxifen for Chemoprevention
Conclusions: While the majority of women who used tamoxifen for primary prevention of breast cancer were likely to benefit, substantial discontinuation of tamoxifen before five years and use by women at risk of serious side effects may attenuate benefits for breast cancer prevention.
Source: JNCI - December 3, 2014 Category: Cancer & Oncology Authors: Nichols, H. B., DeRoo, L. A., Scharf, D. R., Sandler, D. P. Tags: Article Source Type: research

1366p * risk-benefit index of tamoxifen and raloxifene for chemoprevention of korean breast cancer
Conclusions: Women under the age 40 had more benefit than risk from tamoxifen chemoprevention. In the postmenopausal women with a uterus, raloxifene has more favorable risk-benefit index than tamoxifen.Disclosure: All authors have declared no conflicts of interest.
Source: Annals of Oncology - September 24, 2014 Category: Cancer & Oncology Authors: Chang, M. Tags: prevention and screening Source Type: research

Drugs to be offered to women at high risk of breast cancer
The National Institute of Health and Care Excellence (NICE) has today released updated guidelines on the care of women who are at increased risk of breast cancer due to their family history. One of the main changes to the original guidance from 2004 is that NICE now recommends drug treatment with tamoxifen or raloxifene to reduce risk of breast cancer in a specific group of women who are at high risk of breast cancer and have not had the disease. They say that these treatments could help prevent breast cancer in about 488,000 women aged 35 years and older. The updated guideline has also made changes to the recommende...
Source: NHS News Feed - June 25, 2013 Category: Consumer Health News Tags: Cancer Medical practice QA articles Source Type: news

Tamoxifen boost for breast cancer sufferers
Study finds that death rates fall significantly for patients who take the drug for 10 years rather than the standard fiveBreast cancer is less likely to recur if women previously treated for the disease take the drug tamoxifen for 10 years, instead of the recommended five, according to a British study. The study was a component of a larger international trial for which similar results were announced last year.Researchers estimated that, compared with taking no tamoxifen, 10 years of the drug reduces breast cancer death rates by a third in the first 10 years and by half after that. "Until now, there have been doubts whether...
Source: Guardian Unlimited Science - June 2, 2013 Category: Science Tags: The Guardian News Health Medical research Society Drugs UK news Breast cancer Science Source Type: news